Table 3.
Differences at the time of enrollment between patients with and without a history of extrahepatic cancer.
| Variables | Patients with Extrahepatic Cancer (n = 39, 18.7%) |
Patients without Extrahepatic Cancer (n = 170, 81.3%) |
p Value |
|---|---|---|---|
| Sex (M/F) | 28/11 (71.8%/28.2%) | 124/46 (72.9%/27.1%) | 0.845 |
| Age (years) | 67.5 (15) 68.2 ± 9.5 |
66 (14) 64.4 ± 10.9 |
0.098 |
| Weight (Kg) | 85 (13) 84.4 ± 14.9 |
86.5 (30) 90.9 ± 20.7 |
0.206 |
| BMI (Kg/m2) | 27.3 (6.4) 29 ± 4.7 |
29.7 (8.5) 30.8 ± 6 |
0.152 |
| HbA1c (%) | 7.2 (2.6) 7.5 ± 1.5 |
7.2 (2.6) 7.8 ± 2 |
0.563 |
| LDL (mg/dL) | 86 (47) 83.5 ± 31.7 |
91 (62) 96.7 ± 44 |
0.13 |
| HDL (mg/dL) | 47 (16) 45.8 ± 10.9 |
42.5 (14) 43.7 ± 11 |
0.2 |
| Tg (mg/dL) | 119.5 (101) 157.9 ± 107.1 |
150 (97) 178.8 ± 122.5 |
0.114 |
| FIB-4 | 1.13 (0.64) 1.37 ± 0.6 |
0.96 (0.5) 1.1 ± 0.5 |
0.004 |
| Metformin | 27 (69.2%) | 126 (74.1%) | 0.551 |
| DPP-4 inhibitors | 10 (25.6%) | 37 (21.7%) | 0.671 |
| SGLT-2 inhibitors | 14 (35.9%) | 50 (29.4%) | 0.445 |
| GLP-1 analogs | 9 (23.1%) | 60 (35.3%) | 0.186 |
| Sulfonylureas | 4 (10.3%) | 18 (10.6%) | 0.951 |
| Pioglitazone | 2 (5.1%) | 5 (2.9%) | 0.617 |
| Insulin | 18 (46.1%) | 61 (35.9%) | 0.273 |
| Hypertension | 19 (61.5%) | 77 (45.3%) | 0.725 |
| FIB-4 > 1.3 | 18 (46.1%) | 41 (24.1%) | 0.01 |
Variables are expressed as median value and interquartile range (IQR) or number of cases (percentages). (Mean value ± standard deviation (SD) is presented underneath.) M/F: male/female; BMI: body mass index; HbA1c: glycated hemoglobulin A1; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglycerides; DPP-4: dipeptidyl peptidase-4; SGLT-2: Sodium-Glucose Transport Protein-2; GLP-1: glucagon-like peptide-1. The table displays patients’ lipid values and antidiabetic treatment at the study's enrollment time.